What Does Cohance Life’s Q2 FY26 Concall Reveal?

Cohance Life Q2 FY26 concall summary covering revenue trends, CDMO momentum, deferred shipments, margin trajectory, FY26–27 guidance, and strategic capability expansion.

What Does Cohance Life’s Q2 FY26 Concall Reveal About Its Growth Outlook in CDMO, API Plus and Specialty Chemicals?

Cohance Life, operating across CDMO, API Plus, and Specialty Chemicals, delivered a mixed Q2 FY26 performance marked by revenue deferrals but intact long-term strategic visibility. The company continues to reposition itself from a legacy integration-led model to a diversified capability-expansion platform, supported by strong technical talent, deeper global customer presence, and increasing opportunities driven by supply chain diversification away from China. This concall offered clarity on segment-wise traction, execution pipelines, deferred programs and the uplift expected in H2 FY26 and FY27.

The quarter was operationally soft in reported numbers due to shipment delays, shutdown impact and some biotech funding constraints in global markets. However, management commentary highlighted a much healthier underlying demand picture, with progress across late-phase CDMO molecules, oligos pipeline expansion, additional US approvals, and capacity strengthening across multiple sites.

Q2 & H1 FY26 – Financial Highlights

Metric	Q2 FY26	H1 FY26
Revenue	₹5,556M	₹11,039M
EBITDA Margin	23–24%	High-20s%
Material Margin	74.6%	—
Adjusted PAT	—	₹1,323M
Free Cash Flow	₹1.69B	—
Working Capital Days	121 days
Capex	₹1.06B (ADC, Oligos, Debottlenecking)

The company clarified that headline Q2 revenue was depressed primarily due to customer shipment deferrals in the ADC and late-phase CDMO businesses, but adjusted revenue for H1 grew close to 20%. Management reiterated strong execution in capability expansion and improved global market participation.

For intraday market-timing opportunities that align with evolving pharma sentiment, explore our updated Nifty Intraday Call.

Peer Comparison – CDMO & Specialty Manufacturers

Company	Revenue Trend	Margin Profile	Commentary
Aragen	Stable	Mid-20s%	Pipeline steady; biotech softness persists
Syngene	Moderate	Mid-20s%	Execution strong; capex cycle ongoing
Divi’s	Recovering	Healthy	Custom synthesis gain visibility improving

Peers show a blended recovery trajectory, but Cohance’s diversified model offers relatively stronger margin uplift visibility as deferred programs normalise.

Strengths Strong material margin of 74.6% highlighting efficient process economics Diversified 3-vertical structure enabling multi-engine growth Late-phase CDMO approvals and expanding molecule pipeline US FDA clearance for Jadcherla & validation success at Ambernath

Weaknesses Q2 revenue softness driven by deferred shipments Biotech funding slowdown impacting global outsourcing cycles Working capital days elevated at 121

While temporary headwinds affected quarterly visibility, the structural strengths offer durable support for execution recovery.

Opportunities China+1 shift increasing CDMO onboarding pace Oligos platform (ORIGO) with 35 molecules ready for scale-up ADC revenues expected to normalise after deferral window Strong FDF pipeline with semi-regulated market launches

Threats Market uncertainty for smaller biotech clients Any regulatory lag in US, EU or ROW audits Potential margin pressure if material costs rise unexpectedly

Opportunity visibility remains strong across CDMO, Oligos, ADC and API Plus, although regulatory and biotech-cycle risks must be monitored.

Valuation & Investment View

Cohance Life’s fundamentals suggest a steady-to-improving margin outlook, especially as deferred projects start contributing in H2 FY26. With capability expansion, diversified customer onboarding and improving regulatory compliance, FY27 could see a stronger rebound in revenues as guided by management. Margin expansion into the high-20s% range further enhances long-term attractiveness.

For broader sector-linked tactical strategies, review our refined BankNifty Intraday Call.

Investor Takeaway

Cohance Life’s Q2 FY26 concall indicates that while reported numbers saw short-term pressure, the operational visibility underneath remains sound. Investors should watch for revenue realisation from ADC and Oligos programs, improving site utilisation and regulatory milestones. FY27 appears positioned for a healthier recovery as backlogs normalize.

This analytical interpretation is presented by Gulshan Khera, CFP®, providing clarity-driven insights into evolving CDMO and specialty manufacturing trends.

For extended research and market-aligned insights, explore more at Indian-Share-Tips.com, which is a SEBI Registered Advisory Services.

Related Queries on CDMO and Pharma Manufacturing

• How is India’s CDMO sector evolving post global supply chain shifts?
• What drives margin expansion for pharma outsourcing firms?
• How do biotech funding cycles affect CDMO revenues?
• What are key opportunities in oligos manufacturing?
• How do regulatory approvals shape long-term pharma growth?

SEBI Disclaimer: The information provided in this post is for informational purposes only and should not be construed as investment advice. Readers must perform their own due diligence and consult a registered investment advisor before making any investment decisions. The views expressed are general in nature and may not suit individual investment objectives or financial situations.

Cohance Life Q2 FY26, CDMO India, API Plus manufacturers, Specialty chemicals growth, Pharma outsourcing trends